Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prf Technologies Ltd (PRFX)

Prf Technologies Ltd (PRFX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,903
  • Shares Outstanding, K 2,013
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,590 K
  • EBIT $ -6 M
  • EBITDA $ -15 M
  • 60-Month Beta 0.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.23
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -147.33
  • Most Recent Earnings N/A on 08/15/24
  • Next Earnings Date 04/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6110 +49.75%
on 12/30/25
1.5900 -42.45%
on 01/16/26
+0.0170 (+1.89%)
since 12/22/25
3-Month
0.6110 +49.75%
on 12/30/25
1.5900 -42.45%
on 01/16/26
-0.2950 (-24.38%)
since 10/22/25
52-Week
0.6110 +49.75%
on 12/30/25
6.6500 -86.24%
on 01/24/25
-2.1550 (-70.20%)
since 01/22/25

Most Recent Stories

More News
BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

AI-driven monitoring and analytics solutions addressing the growing demand for energy efficiency in large-scale solar and critical infrastructure projects across the Middle East.

PRFX : 0.9250 (-2.17%)
PainReform Ltd. Reports Partial Topline Data from Phase 3 Trial of PRF-110 for Post-Surgical Pain Management

PainReform reports positive Phase 3 trial findings for PRF-110 in postoperative pain but faces data inconsistencies for key metrics.Quiver AI SummaryPainReform Ltd. announced the receipt of partial topline...

PRFX : 0.9250 (-2.17%)
PainReform to Present at the Microcap Conference in Atlantic City

Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...

PRFX : 0.9250 (-2.17%)
PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

TEL AVIV, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the...

PRFX : 0.9250 (-2.17%)
PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...

PRFX : 0.9250 (-2.17%)
PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

TEL AVIV, Israel, March 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty...

PRFX : 0.9250 (-2.17%)

Business Summary

PainReform Ltd.is a clinical stage specialty pharmaceutical company. It engages in the development of products for the treatment of pain. The company's product pipeline includes PRF-110, a product based on local anesthetic ropivacaine, which is in clinical stage. PainReform Ltd.is based in Herzeliya,...

See More

Key Turning Points

3rd Resistance Point 1.1010
2nd Resistance Point 1.0397
1st Resistance Point 0.9926
Last Price 0.9250
1st Support Level 0.8842
2nd Support Level 0.8229
3rd Support Level 0.7758

See More

52-Week High 6.6500
Fibonacci 61.8% 4.3431
Fibonacci 50% 3.6305
Fibonacci 38.2% 2.9179
Last Price 0.9250
52-Week Low 0.6110

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar